Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,728 INR | -0.59% | -2.00% | -10.19% |
08/04 | Nicomac Machinery and RP Advisory Services Reportedly Likely to Sell 4.4% Stake in Gland Pharma via Block Deals | CI |
08/04 | Gland Pharma Gets US FDA Approval for Eribulin Mesylate Injection | MT |
Sales 2024 * | 56.49B 678M | Sales 2025 * | 63.2B 758M | Capitalization | 285B 3.41B |
---|---|---|---|---|---|
Net income 2024 * | 8.48B 102M | Net income 2025 * | 11.02B 132M | EV / Sales 2024 * | 4.55 x |
Net cash position 2024 * | 27.5B 330M | Net cash position 2025 * | 31.55B 378M | EV / Sales 2025 * | 4.01 x |
P/E ratio 2024 * |
33.5
x | P/E ratio 2025 * |
25.8
x | Employees | 4,585 |
Yield 2024 * |
0.1% | Yield 2025 * |
0.2% | Free-Float | 38.38% |
Latest transcript on Gland Pharma Limited
1 day | -0.59% | ||
1 week | -2.00% | ||
Current month | -6.34% | ||
1 month | -3.52% | ||
3 months | -8.99% | ||
6 months | +12.41% | ||
Current year | -10.19% |
Managers | Title | Age | Since |
---|---|---|---|
Srinivas Sadu
CEO | Chief Executive Officer | 55 | 01/00/01 |
Director of Finance/CFO | - | 30/19/30 | |
C. S. Venkatesan
CTO | Chief Tech/Sci/R&D Officer | - | 01/98/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fang Yao
BRD | Director/Board Member | 54 | 10/22/10 |
Srinivas Sadu
CEO | Chief Executive Officer | 55 | 01/00/01 |
Yiu Kwan Lau
CHM | Chairman | 69 | 10/19/10 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 1,728 | -0.59% | 166,537 |
25/24/25 | 1,739 | -1.03% | 74,251 |
24/24/24 | 1,757 | -1.41% | 89,617 |
23/24/23 | 1,782 | +0.28% | 76,362 |
22/24/22 | 1,777 | +0.75% | 86,990 |
Delayed Quote NSE India S.E., April 26, 2024 at 05:13 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.19% | 3.41B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- GLAND Stock